Health In Tech, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
Health In Tech filed an investor presentation reaffirming mid-2026 revenue guidance of $45–50M (35–50% growth) but reported Q2 2026 revenue of $8.1M (down 14% YoY) and Adjusted EBITDA loss of $1.3M versus profit of $1.6M in Q2 2025. Year-to-date 1H 2026 revenue fell 3% to $16.8M with Adjusted EBITDA loss of $2.6M versus profit of $2.8M in 1H 2025. Gross margin compressed from 67.7% (Q2 2025) to 48.7% (Q2 2026). No counterparty transactions disclosed; this is a guidance reaffirmation tied to deteriorating operational performance.
Why this rating
Margin collapse and profitability flip to losses—yet guidance reaffirmed at $45–50M—creates credibility tension. Relative to $12.7M market cap and $8.1M Q2 revenue, the company is mid-sized; a 14% revenue decline with 50%+ margin compression and EBITDA swings from +$1.6M to –$1.3M are material warning signs. Not imminent bankruptcy, but trajectory deterioration warrants investor concern.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.